DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Patients eligible for the study will receive R-DA-EDOCH as the induction therapy and be
evaluated by PET CT after the fourth cycle. Patients achieve CR at interim-PET(Deauville
score 1-3) will receive either ASCT or the remaining 4 cycles of R-DA-EDOCH, while those
achieve PR(Deauville score 4-5) will be rescued by two courses of R(2)-DHAP and then be
revaluated by the second interim-PET. Patients who achieved CR+good PR(Deauville score 4)
after the rescue therapy will be consolidated with ASCT,and those remain in PR(Deauville
score 5) will receive other rescue treatments(including ASCT+CAR T).